ArticleFrontiers in pharmacology2025
DTGHAT: multi-molecule heterogeneous graph transformer based on multi-molecule graph for drug-target identification.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Dual-module aCAR-iCAR NK cells for solid tumors: cascade resistance mechanisms, AI-driven engineering, and precision stratification.Frontiers in immunology · 2026Review
- Scaling Biomedical Text-Mining: Transformers, GenAI, and Drug Discovery.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Graph Neural Network-Based Toxicity Prediction by Integrating Molecular Fingerprints and Knowledge Graph Features.Toxics · 2025Article
- Enhancing drug repositioning: A multi-class ensemble model for drug-target interaction prediction with action type categorization.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Drug target identification is a fundamental step in drug discovery and plays a pivotal role in new therapies development. Existing computational methods focus on the direct interactions between drugs and targets, often ignoring the complex interrelationships between drugs, targets and various biomolecules in the human system. Method: To address this limitation, we propose a novel prediction model named DTGHAT (Drug and Target Association Prediction using Heterogeneous Graph Attention Transformer based on Molecular Heterogeneous). DTGHAT utilizes a graph attention transformer to identify novel targets from 15 heterogeneous drug-gene-disease networks characterized by chemical, genomic, phenotypic, and cellular networks. Result: In a 5-fold cross-validation study, DTGHAT achieved an area under the receiver operating characteristic curve (AUC) of 0.9634, which is at least 4% higher than current state-of-the-art methods. Characterization ablation experiments highlight the importance of integrating biomolecular data from multiple sources in revealing drug-target interactions. In addition, a case study on cancer drugs further validates DTGHAT's effectiveness in predicting novel drug target identification. DTGHAT is free and available at: https://github.com/stella-007/DTGHAT.git.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.